YSOPIA Bioscience is a French clinical stage biotech company specializing in the research and development of therapeutic innovations harnessing the potential of the gut microbiome.

Founded in 2010, YSOPIA develops groundbreaking biotherapies using single-strain keystone bacteria. The Company has completed a Phase 1 clinical trial evaluating its drug-candidate, Xla1, on obesity and associated metabolic diseases. YSOPIA’s portfolio also includes three other innovative programs addressing chronic indications with substantial unmet medical needs (inflammatory diseases and mood disorders).

Supported by leading venture capital investors, such as Seventure Partners, and family offices, YSOPIA Bioscience has established collaborative projects worldwide with renowned scientific institutions and academic experts to maintain the highest standards in the development of its innovative biotherapeutics.

YSOPIA Bioscience is an active member of the Alliance Promotion Microbiote, an initiative bringing together more than 20 industrial groups, competitiveness clusters and research organizations to promote the microbiota sector and to position France as a European leader in the field.